Aribio Lab is expanding its research and development scope into preventive vaccines for degenerative neurological diseases such as Alzheimer's disease and anti-aging immunotherapy, securing a new growth strategy. Aribio Lab is an immunity and vaccine specialist company under the Aribio Group.
On the 10th, Aribio Lab announced that it will participate in the "Korean Academy of Immunology International Conference" (KAI International Meeting 2026), the country's largest immunology academic event, scheduled to be held from the 12th to the 14th at Songdo Convention Center in Incheon.
At this event, Aribio Lab will introduce its proprietary immune adjuvant platform technology and the development status of key vaccine pipelines, and disclose a medium- to long-term vision for future businesses in the fields of neuroimmunology and anti-aging. Through this, the company aims to formalize its strategy to broaden its business structure, which has centered on infectious disease vaccines, into neuroimmunology and immune aging regulation.
Aribio Lab's most advanced clinical pipeline is the recombinant shingles preventive vaccine "CVI-VZV-001." Safety and a 100% seroprotection rate were confirmed in Phase 1 clinical trials. The second dose of the Phase 2 clinical trial targeting 135 adults aged 50 and older has been completed. The company plans to enter Phase 3 after announcing top-line (key metrics) results in the first quarter of next year. Since domestic recombinant shingles vaccines rely entirely on imports, localization carries significant meaning.
Aribio Lab is also developing an mRNA-based immunotherapy for cancer as a project under the National New Drug Development Program. The hepatitis B therapeutic vaccine "CVI-HBV-002" significantly increased HBV (hepatitis B virus)-specific T-cell responses compared to placebo in Phase 2b clinical trials. Aribio Lab is considering combination therapy with siRNA therapeutics and expansion into preventive vaccines. As a Ministry of Health and Welfare project, the company is also researching the country's first recombinant Japanese encephalitis vaccine.
The core competitiveness of Aribio Lab's vaccine technology lies in its proprietary immune adjuvant platforms "L-pampo" and "Lipo-pam." These two technologies simultaneously stimulate innate immune receptors "TLR1/2" and "TLR3," inducing both humoral and cellular immunity. Because they can be combined with various antigens, they can be expanded not only to preventive vaccines but also to therapeutic vaccines and immunotherapy fields.
In particular, Lipo-pam has been uniquely listed among domestic companies in the "Vaccine Adjuvant Library" of the Coalition for Epidemic Preparedness Innovations (CEPI) under the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This signifies recognition as part of the global pandemic response system. Aribio Lab plans to pursue commercialization, including joint research with global vaccine developers, adjuvant supply, and technology transfer, leveraging Lipo-pam.
Aribio has secured capabilities in multinational clinical trials and central nervous system disease research through the global Phase 3 clinical trial of its oral Alzheimer's disease treatment "AR1001" (generic name: mirodenafil). Aribio Lab is expected to focus on researching preventive approaches for degenerative neurological diseases and neuroimmune regulation technologies, adding its immune adjuvant platform and vaccine development experience.
Recently, following the completion of Japanese patent registration for AR1001, Aribio has been strengthening its commercialization foundation by receiving a notice of scheduled patent registration from the European Korean Intellectual Property Office (EPO). The company is conducting a third-party allotment rights offering (paid-in capital increase) totaling 42.5 billion won targeting its partner, China's Fosun Pharma.
Vice President Jeon Eun-young of Aribio Lab (Head of Research Institute) stated, "The immune adjuvant platform accumulated over a long period is a foundational technology that can be expanded beyond infectious disease vaccines to various immune-related diseases." She added, "While securing the clinical results of the shingles vaccine without delay, we will seek differentiated research and development opportunities in the fields of neuroimmunology, degenerative neurological diseases, and anti-aging."
CEO Chung Jae-jun of Aribio Lab stated, "The Aribio Group possesses mutually complementary technological foundations: AR1001's global clinical capabilities and Aribio Lab's proprietary immune platform." He added, "By combining these two capabilities, we will build a Jeonju-based brain health portfolio connecting treatment and prevention, strengthening our medium- to long-term growth foundation."
in THEBIO
